Comparison of Conventional Therapies With Stem Cell Therapy in the Treatment of Heart Disease

Heart disease remains a leading cause of mortality and morbidity worldwide. Conventional treatment options, including pharmacological therapies and surgical interventions, have been effective in managing symptoms and preventing further progression of the disease.

This study aims to compare the efficacy and safety of stem cell therapy with conventional therapies in patients with heart disease.

This prospective cohort study was conducted at Nottingham University Hospital, NHS, UK, from January 2024 to December 2024. A total of 95 patients were added to the study. Patients were divided into two groups: 47 patients received stem cell therapy, and 48 patients received conventional therapy, which included pharmacological treatments, surgical procedures, or implantable devices. The primary outcomes assessed were improvement in left ventricular ejection fraction (LVEF), exercise capacity measured by the six-minute walk test, and quality of life using the Minnesota Living with Heart Failure Questionnaire (MLHFQ).

The stem cell therapy group showed significant improvements in left ventricular ejection fraction (LVEF), increasing from 30.2% ± 8.4% at baseline to 43.6% ± 9.7% after six months (p < 0.01). In contrast, the conventional therapy group showed a smaller increase in LVEF, from 32.5% ± 7.9% to 36.8% ± 8.1% (p = 0.04). Exercise capacity, measured by the six-minute walk test, improved by 80 meters in the stem cell group compared to a 30-meter improvement in the conventional group (p < 0.001). Quality of life, assessed using the MLHFQ, improved significantly more in the stem cell group, with a reduction in score from 56.2 ± 15.3 to 38.5 ± 12.1 (p < 0.001), versus a reduction from 54.7 ± 14.5 to 48.6 ± 13.2 (p = 0.02) in the conventional therapy group. Hospitalization rates were lower in the stem cell group (10.6%) compared to the conventional group (27.1%) (p = 0.03).

It is concluded that stem cell therapy offers significant advantages over conventional therapies in the management of heart disease, particularly in terms of improving cardiac function, exercise capacity, and quality of life. Unlike previous studies that evaluated stem cell therapy in isolation or without direct comparison, this article uniquely provides a head-to-head analysis against conventional treatments in a prospective cohort, offering practical insights into how stem cell therapy may complement or outperform current standards of care.